Dmytro Rudoy

This study shows ERK signaling promotes resistance to TRK inhibitors in NTRK fusion-driven glioma mouse models and suggests MEK inhibition as a potential combination therapy.

This study shows that acute CDK12 loss in prostate cancer causes HR deficiency via polyadenylation, but chronic loss leads to adaptation, making PARP inhibitors ineffective and suggesting CDK13 targeting as a new therapeutic approach.

The paper shows that aggressive high-grade NF2 mutant meningiomas have reduced YAP1 activity due to increased VGLL4 and FAT3/4 expression, linked to higher recurrence risk.